Implantable cardioverter-defibrillator implementation in acute heart failure syndromes: Unanswered questions

Heart Failure Reviews

Volumn 16, Issue 5, 2011, Pages 477-480

  Wang, Norman C ^a   Piccini, Jonathan P ^b   Gheorghiade, Mihai ^c  

^a UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

^b DUKE CLINICAL RESEARCH INSTITUTE   (United States)

^c NORTHWESTERN UNIVERSITY   (United States)

Author keywords

Heart failure; Hospitalization; Implantable cardioverter defibrillator; Mortality

Indexed keywords

CANDESARTAN; METOPROLOL; PLACEBO; TOLVAPTAN;

ACUTE HEART FAILURE; ACUTE HEART INFARCTION; CONGESTIVE HEART FAILURE; DEFIBRILLATOR; DISEASE ASSOCIATION; HEART FAILURE; HEART LEFT VENTRICLE EJECTION FRACTION; HOSPITAL DISCHARGE; HUMAN; MORTALITY; PRIMARY PREVENTION; REVIEW; SECONDARY PREVENTION; SUDDEN DEATH;

ACUTE DISEASE; ARRHYTHMIAS, CARDIAC; CRITICAL PATHWAYS; DEATH, SUDDEN, CARDIAC; DEFIBRILLATORS, IMPLANTABLE; ELECTRIC COUNTERSHOCK; HEART FAILURE; HEART RATE; HEART VENTRICLES; HUMANS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SEVERITY OF ILLNESS INDEX; SURVIVAL RATE;

EID: 80052498097     PISSN: 13824147     EISSN: 15737322     Source Type: Journal    
DOI: 10.1007/s10741-011-9243-5     Document Type: Review

References (18)

1. The Antiarrhythmics Versus Implantable Defibrillators (AVID) Investigators (1997) A comparison of antiarrhythmic-drug therapy with implantable defibrillators in patients resuscitated from near-fatal ventricular arrhythmias. N Engl J Med 337:1576-1583
2. Moss AJ, Zareba W, Hall WJ, Klein H, Wilber DJ, Cannom DS, Daubert JP, Higgins SL, Brown MW, Andrews ML (2002) for the Multicenter Automatic Defibrillator Implantation Trial II Investigators. N Engl J Med 346:877-883
3. Bardy GH, Lee KL, Mark DB, Poole JE, Packer DL, Boineau R, Domanski M, Troutman C, Anderson J, Johnson G, McNulty SE, Clapp-Channing N, Davidson-Ray LD, Fraulo ES, Fishbein DP, Luceri RM, Ip JH, for the Sudden Cardiac Death in Heart Failure Trial (SCD-HeFT) Investigators (2005) Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure. N Engl J Med 352:225-237 (Pubitemid 40110811)
4. Hunt SA, Abraham WT, Chin MH, Feldman AM, Francis GS, Ganiats TG, Jessup M, Konstam MA, Mancini DM, Michl K, Oates JA, Rahko PS, Silver MA, Stevenson LW, Yancy CW (2009) 2009 focused update incorporated into the ACC/AHA 2005 guidelines for the diagnosis and management of heart failure in adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 53:e1-e90
5. MERIT-HF Study Group (1999) Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF). Lancet 353: 2001-2007
6. Solomon SD, Dobson J, Pocock S, Skali H, McMurray JJV, Granger CB, Yusuf S, Swedberg K, Young JB, Michelson EL, Pfeffer MA, for the Candesartan in Heart failure Assessment of Reduction in Mortality and morbidity (CHARM) Investigators (2007) Influence of nonfatal hospitalization for heart failure on subsequent mortality in patients with chronic heart failure. Circulation 116:1482-1487 (Pubitemid 47480639)
7. O'Connor CM, Miller AB, Blair JEA, Konstam MA, Wedge P, Bahit MC, Carson P, Haass M, Hauptmann PJ, Metra M, Oren RM, Patten R, Piña I, Roth S, Sackner-Bernstein JD, Traver B, Cook T, Gheorghiade M, for the Efficacy of Vasopressin Antagonism in heart Failure Outcome Study with Tolvatpan (EVEREST) (2010) Causes of death and rehospitalization in patients hospitalized with worsening heart failure and reduced left ventricular ejection fraction: Results from efficacy of vasopressin antagonism in heart failure outcome study with tolvaptan (EVEREST) program. Am Heart J 159:841-9.e1
8. Wang NC, Maggioni AP, Konstam MA, Zannad F, Krasa HB, Burnett KC Jr, Grinfeld L, Swedberg K, Udelson JE, Cook T, Traver B, Zimmer C, Orlandi C, Gheorghiade M (2008) for the Efficacy of Vasopressin Antagonism in Heart Failure Outcome Study With Tolvaptan (EVEREST) Investigators. Clinical implications of QRS duration in patients hospitalized with worsening heart failure and reduced left ventricular ejection fraction. JAMA 299(22):2656-2666 (Pubitemid 351831595)
9. Hohnloser SH, Kuck KH, Dorian P, Roberts RS, Hamptom JR, Hatala R, Fain E, Gent M, Connolly SJ, on behalf of the DINAMIT Investigators (2004) Prophylactic use of an implantable cardioverter-defibrillator after acute myocardial infarction. N Engl J Med 351:2481-2488 (Pubitemid 39603155)
10. Nazarian S, Maiserl WH, Miles JS, Tsang S, Stevenson LW, Stevenson WG (2005) Impact of implantable cardioverter defibrillators on survival and recurrent hospitalization in advanced heart failure. Am Heart J 150:955-960 (Pubitemid 41607774)
11. Hernandez AF, Fonarow GC, Hammill BG, Al-Khatib SM, Yancy CW, O'Connor CM, Schulman KA, Peterson ED, Curtis LH (2010) Clinical effectiveness of implantable cardioverterdefibrillators among Medicare beneficiaries with heart failure. Circ Heart Fail 3:7-13
12. Rubin DB (1978) Bayesian inference for causal effects: the role of randomization. Ann Stat 6:34-58
13. Wang NC, Piccini JP, Konstam MA, Maggioni AP, Traver B, Swedberg K, Udelson JE, Zannad F, Cook T, O'Connor CM, Miller AM, Grinfeld L, Gheorghiade M, for the EVEREST Investigators (2010) Implantable cardioverter-defibrillators in patients hospitalized for heart failure with chronically reduced left ventricular ejection fraction. Am J Ther 17:e78-e87
14. Hernandez AF, Fonarow GC, Liang L, Al-Khatib SM, Curtis LH, LaBresh KA, Yancy CW, Albert NM, Peterson ED (2007) Sex and racial differences in the use of implantable cardioverterdefibrillators among patients hospitalized with heart failure. JAMA 298(13):1525-1532 (Pubitemid 47529386)
15. Stevenson LW, Desai AS (2006) Selecting patients for discussion of the ICD as primary prevention for sudden death in heart failure. J Card Fail 12(6):407-412 (Pubitemid 46110776)
16. Gheorghiade M, Pang P (2009) Acute heart failure syndromes. J Am Coll Cardiol 53:557-573
17. Lucas C, Johnson W, Hamilton MA, Fonarow GC, Woo MA, Flavell CM, Creaser JA, Stevenson LW (2000) Freedom from congestion predicts good survival despite previous class IV symptoms of heart failure. Am Heart J 140:840-847
18. Chung MK, Szymkiewicz SJ, Shao M, Zishiri E, Niebauer MJ, Lindsay BD, Tchou PJ (2010) Aggregate national experience with the wearable cardioverter-defibrillator: event rates, compliance, and survival. J Am Coll Cardiol 56:194-203